Related Experiment Video
Updated: Jul 18, 2026
03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
A novel analytical method for assessing glucose variability: using CGMS in type 1 diabetes mellitus
Anthony L McCall1, Daniel J Cox, John Crean
1Division of Endocrinology and Center for Diabetes and Hormone Excellence, Department of Internal Medicine, University of Virginia, Charlottesville, Virginia 22908, USA. alm3j@virginia.edu
Diabetes Technology & Therapeutics
|November 18, 2006
Summary
Pramlintide treatment in type 1 diabetes significantly reduced blood glucose (BG) fluctuations and hyperglycemia risk without increasing hypoglycemia. Novel analytical methods effectively assessed BG variability, offering insights beyond glycosylated hemoglobin levels.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Marked blood glucose (BG) fluctuations increase diabetes complication risks.
- Acute BG excursions are common and not fully captured by HbA1c.
- Continuous Glucose Monitoring System (CGMS) data can assess BG variability.
Purpose of the Study:
- Evaluate novel analytical methods for BG variability using CGMS data.
- Assess the sensitivity of these methods in patients treated with pramlintide.
- Determine pramlintide's effect on BG fluctuations and glycemic extremes.
Main Methods:
- Retrospective analysis of 24-h CGMS profiles from 22 type 1 diabetes patients.
- Patients received placebo or 30 microg pramlintide three times daily for 4 weeks.
- Calculated BG variability, low BG index (LBGI), and high BG index (HBGI).
Main Results:
- Pramlintide significantly lowered mean postprandial BG rate of change versus placebo (0.87 vs. 1.21 mg/dL/min).
- No changes in average glycemia were observed.
- HBGI and LBGI indicated reduced hyperglycemia risk without increased hypoglycemia risk.
Conclusions:
- Novel methods effectively assess BG variability and glycemic extremes.
- These methods capture pharmacological intervention effects not seen with HbA1c.
- Pramlintide demonstrates potential in managing BG fluctuations and hyperglycemia.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:12Type I Diabetes I: Introduction
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...